For instance, dual-targeting CD19/CD22 CAR T-cell therapy has shown enhanced OS and progression-free survival (PFS) in Acute Myeloid Leukemia (AML) patients compared to single-antigen CAR T-cell therapy [129,130,131,132,133] (Figure 7). Here, CD19 is linked to acute myeloid leukemia.